The DEA Cannabis Hearing Calendar: Every Key Date Operators Should Know

The hearing many in the cannabis industry have been waiting for officially begins today.

Starting June 29, the U.S. Drug Enforcement Administration (DEA) will convene a formal administrative hearing in Arlington, Virginia, to determine whether marijuana not already covered under the federal government’s April medical rescheduling order should also move from Schedule I to Schedule III of the Controlled Substances Act.

For operators, investors, lenders, ancillary businesses, and policymakers, this is the beginning of a process that could influence taxation, research, capital formation, banking, compliance, and the future structure of the legal cannabis market for years to come.

Here’s what happens each day—and why it matters.

June 29: The Government Makes Its Case

The hearing opens with the federal government defending its proposal to move marijuana to Schedule III.

This is an unusual position for the DEA, an agency that spent decades enforcing federal marijuana prohibition. Yet under the current rulemaking process, the government bears the burden of demonstrating why rescheduling is supported by science, medicine, and federal law.

Government witnesses are expected to focus on two key issues: whether marijuana has a “currently accepted medical use” and whether the Department of Health and Human Services’ scientific review supports Schedule III.

For executives and investors, today’s testimony establishes the evidentiary foundation on which the remainder of the hearing will build.

July 2: Workplace Safety Takes Center Stage

The National Drug & Alcohol Screening Association (NDASA) presents its case against rescheduling.

Expect testimony centered on workplace drug testing, employer liability, impaired workers, and occupational safety.

Businesses with large workforces, transportation operations, or safety-sensitive employees should pay particular attention, as these discussions could influence future employment policies regardless of how the rescheduling process ultimately concludes.

July 6: Public Health Arguments

Smart Approaches to Marijuana (SAM) presents its opposition.

The organization is expected to focus on public health, youth access, addiction, and procedural arguments challenging the government’s scientific review.

These issues have also surfaced in parallel litigation before the U.S. Court of Appeals, making this testimony particularly relevant for understanding potential legal challenges after the hearing concludes.

July 7–13: Expert Testimony

Several organizations and expert witnesses will present testimony throughout the following week.

July 7 features DUID Victim Voices, an organization representing victims of drug-impaired driving.

On July 8, physician Dr. Kenneth Finn is expected to discuss medical concerns associated with marijuana use.

The Tennessee Bureau of Investigation appears on July 10 to address law enforcement and operational considerations.

On July 13, pharmacist Dr. Phillip Drum is scheduled to testify regarding pharmaceutical and clinical issues.

Collectively, these witnesses will help shape the administrative record that ultimately supports—or challenges—the government’s proposed rule.

July 14: States Close The Hearing

The final scheduled testimony comes from the states of Nebraska, Idaho, Indiana, and Louisiana.

The states are expected to argue against broader rescheduling, raising concerns over federal authority, public policy, and implementation.

By the close of testimony, every designated participant opposing rescheduling will have presented their case.

One Of The Hearing’s Biggest Stories Is Who Isn’t There

Perhaps the most unusual aspect of the proceeding is that every designated outside participant opposes rescheduling.

Organizations supporting reform—including NORML, the Drug Policy Alliance, and other advocacy groups—were denied participation after the DEA determined they were not “adversely affected or aggrieved” by a rule they support.

As a result, the government will defend its proposal while seven designated opponents cross-examine witnesses and present competing evidence.

The hearing therefore reflects an unusual procedural dynamic rather than a traditional debate between supporters and opponents.

The Hearing Doesn’t Decide The Outcome

One of the biggest misconceptions surrounding the proceeding is that the hearing itself determines whether marijuana moves to Schedule III.

It does not.

Its purpose is to build the official administrative record.

After testimony concludes, Chief Administrative Law Judge Derek Julius will review the evidence and issue a recommended decision.

That recommendation is then submitted to the DEA Administrator, who will determine whether to adopt, modify, or reject the proposed rule.

Any final action is expected to face additional judicial review.

Why This Matters For Business

For operators, this hearing is about far more than scheduling.

If broader rescheduling ultimately moves forward, the implications extend well beyond tax policy.

The discussion touches virtually every aspect of the industry, including research, physician participation, DEA registration, manufacturing standards, banking, institutional investment, insurance reimbursement, and access to capital.

Many executives believe the industry’s next competitive advantages will not simply come from cultivation capacity or retail footprint, but from operational excellence, regulatory readiness, clinical data, manufacturing quality, and stronger integration with mainstream healthcare.

Regardless of the outcome, the hearing marks a turning point in the federal conversation.

The debate is gradually shifting away from whether marijuana should exist and toward how it should be regulated.

That transition may ultimately prove more important than the scheduling decision itself.

IgniteIt will continue covering each phase of the hearing, translating testimony, legal developments, and regulatory changes into practical business insights for operators, investors, and ancillary companies.

The conversation will continue in person on September 18 at the IgniteIt Colorado Market Spotlight in Denver, where industry leaders will examine the policy, capital, technology, and operational strategies shaping the next chapter of the cannabis industry.